Last reviewed 2026-04-23 · How we verify

MenBvac

MenBvac is a meningococcal B vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B.

MenBvac is a meningococcal B vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B.

At a glance

Mechanism of action

The vaccine contains recombinant meningococcal B surface proteins that trigger both humoral and cellular immune responses. This leads to the generation of protective antibodies and memory B cells that can recognize and neutralize the pathogen upon natural exposure, preventing invasive meningococcal disease.

Approved indications

• Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B

Common side effects

• Injection site pain/erythema
• Fever
• Myalgia
• Fatigue

Key clinical trials

• Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults (PHASE2)
• Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Vaccinated With MenBVac® (Extension MenbVac) (PHASE3)
• Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC)
• Immunogenicity After Two Doses of Meningococcal Outer Membrane Vesicle Vaccine MenBVac
• Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Have to be Vaccinated MenBVac®

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.